Trial · NCT01307397
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.0 | Vemurafenib | 52.8 | Percentage of participants | ||
| Percentage of Participants With at Least 1 AE Leading to Study Drug Interruption or Drug Discontinuation | Vemurafenib | AE Leading to Drug Discontinuation | 7.0 | Percentage of participants | |
| Percentage of Participants With at Least 1 AE Leading to Study Drug Interruption or Drug Discontinuation | Vemurafenib | AE Leading to Study Drug Interruption | 34.0 | Percentage of participants | |
| Percentage of Participants With AEs of Special Interest | Vemurafenib | Arthralgia | 42.3 | Percentage of participants | |
| Percentage of Participants With AEs of Special Interest | Vemurafenib | Rash | 47.9 | Percentage of participants | |
| Percentage of Participants With AEs of Special Interest | Vemurafenib | Photosensitivity | 28.4 | Percentage of participants | |
| Percentage of Participants With AEs of Special Interest | Vemurafenib | Fatigue | 36.8 | Percentage of participants | |
| Percentage of Participants With AEs of Special Interest | Vemurafenib | Cutaneous SCC | 14.6 | Percentage of participants | |
| Percentage of Participants With AEs of Special Interest | Vemurafenib | Non Cutaneous SCC | 0.1 | Percentage of participants | |
| Percentage of Participants With AEs of Special Interest | Vemurafenib | New Primary Melanoma | 1.7 | Percentage of participants | |
| Percentage of Participants With AEs of Special Interest | Vemurafenib | GI Polyps | 0.03 | Percentage of participants | |
| Percentage of Participants With AEs of Special Interest | Vemurafenib | Pancreatitis | 0.2 | Percentage of participants | |
| Percentage of Participants With AEs of Special Interest | Vemurafenib | Potentiation of radiation toxicity | 1.4 | Percentage of participants | |
| Percentage of Participants With AEs of Special Interest | Vemurafenib | Prolongation of Cardiac Repolarization/ Arrhythmia | 17.0 | Percentage of participants | |
| Percentage of Participants With AEs of Special Interest | Vemurafenib | Other primary malignancy | 3.2 | Percentage of participants | |
| Percentage of Participants With AEs of Special Interest | Vemurafenib | Liver Injury | 14.1 | Percentage of participants | |
| Mean Cumulative Dose of Vemurafenib | Vemurafenib | 501.283 | Standard Deviation 510.9121 | Grams | |
| Duration of Vemurafenib Treatment | Vemurafenib | Exposure excluding interruptions | 9.383 | Standard Deviation 9.6755 | Months |
| Duration of Vemurafenib Treatment | Vemurafenib | Exposure including interruptions | 9.724 | Standard Deviation 9.9072 | Months |
| Mean Total Vemurafenib Dose Per Day | Vemurafenib | Average Total Dose Per Day Excluding Interruptions | 1.802 | Standard Deviation 0.2314 | Grams |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01307397/results